Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg") - PubMed

Affiliations

• PMID: 1973167

Free article

Case Reports

Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg")

H H Watzke et al. J Biol Chem. 1990.

Free article

Abstract

Factor X (FX) "Vorarlberg" is a congenital FX deficiency characterized clinically by a mild bleeding tendency. Homozygous individuals have a FX activity of less than 10% in the extrinsic system and 25% in the intrinsic system. FX antigen is 20%. Using molecular techniques, two point mutations were detected in the coding sequence of the FX Vorarlberg gene: a G----A at base pair 160 in exon II resulting in a change of Gla14 (GAA) to Lys (AAA); a G----A at base pair 424 in exon V resulting in a change from Glu102 (GAG) to Lys (AAG). The mutations abolished a TaqI restriction site in exon II and an MnlI site in exon V. To determine whether these mutations are present on one or on both alleles, restriction analyses of amplified exon II and exon V fragments were performed. Analysis of the pedigree showed that the genotype for the mutation on exon II (homozygous versus heterozygous) correlates with the severity of the phenotypic coagulation defect. We therefore conclude that the mutation in exon II is responsible for the functional defect in FX Vorarlberg. We have also purified the mutant FX protein from patient plasma. Purified FX Vorarlberg is indistinguishable from normal FX on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Its activity is 15% of normal FX upon activation with factor VIIa/tissue factor, 75% upon activation with factor IXa/factor VIIIa, and 100% upon activation with RVV. Activation at varying Ca2+ concentrations shows that the affinity of FX Vorarlberg for Ca2+ is decreased. Factor Xa Vorarlberg is able to convert prothrombin at a normal rate but also shows decreased affinity for Ca2+ in this interaction. Upon addition of Ca2+, FX Vorarlberg does not undergo the same conformational change as normal FX. Our data show that FX Vorarlberg has a decreased affinity for Ca2+ which impedes a normal conformational change. This leads to a decreased rate of activation by factor VIIa/tissue factor and by factor IXa. The decrease is much more marked for the extrinsic than for the intrinsic pathway.

Similar articles

• Factor X Friuli Coagulation Disorder: Almost 50 Years Later.

  Girolami A, Cosi E, Santarossa C, Ferrari S, Girolami B, Lombardi AM. Girolami A, et al. Clin Appl Thromb Hemost. 2018 Jan;24(1):33-40. doi: 10.1177/1076029616686423. Epub 2016 Dec 29. Clin Appl Thromb Hemost. 2018. PMID: 28030967 Free PMC article. Review.

• The impact of Glu102Lys on the factor X function in a patient with a doubly homozygous factor X deficiency (Gla14Lys and Glu102Lys).

  Forberg E, Huhmann I, Jimenez-Boj E, Watzke HH. Forberg E, et al. Thromb Haemost. 2000 Feb;83(2):234-8. Thromb Haemost. 2000. PMID: 10739379

• The missense Thr211Pro mutation in the factor X activation peptide of a bleeding patient causes molecular defect in the clotting cascade.

  Ding Q, Shen Y, Yang L, Wang X, Rezaie AR. Ding Q, et al. Thromb Haemost. 2013 Jul;110(1):53-61. doi: 10.1160/TH13-03-0184. Epub 2013 May 16. Thromb Haemost. 2013. PMID: 23677006 Free PMC article.

• Analysis of the novel factor X gene mutation Glu51Lys in two families with factor X-Riyadh anomaly.

  Al-Hilali A, Wulff K, Abdel-Razeq H, Saud KA, Al-Gaili F, Herrmann FH. Al-Hilali A, et al. Thromb Haemost. 2007 Apr;97(4):542-5. Thromb Haemost. 2007. PMID: 17393015

• Complex history of the discovery and characterization of congenital factor X deficiency.

  Girolami A, Cosi E, Sambado L, Girolami B, Randi ML. Girolami A, et al. Semin Thromb Hemost. 2015 Jun;41(4):359-65. doi: 10.1055/s-0034-1544000. Epub 2015 Apr 14. Semin Thromb Hemost. 2015. PMID: 25875733 Review.

Cited by

• Factor XKetchikan: a variant molecule in which Gly replaces a Gla residue at position 14 in the light chain.

  Kim DJ, Thompson AR, James HL. Kim DJ, et al. Hum Genet. 1995 Feb;95(2):212-4. doi: 10.1007/BF00209404. Hum Genet. 1995. PMID: 7860069

• Factor X Friuli Coagulation Disorder: Almost 50 Years Later.

  Girolami A, Cosi E, Santarossa C, Ferrari S, Girolami B, Lombardi AM. Girolami A, et al. Clin Appl Thromb Hemost. 2018 Jan;24(1):33-40. doi: 10.1177/1076029616686423. Epub 2016 Dec 29. Clin Appl Thromb Hemost. 2018. PMID: 28030967 Free PMC article. Review.

• Genotypic analysis of N-ethyl-N-nitrosourea-induced mutations by Taq I restriction fragment length polymorphism/polymerase chain reaction in the c-H-ras1 gene.

  Chiocca SM, Sandy MS, Cerutti PA. Chiocca SM, et al. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5331-5. doi: 10.1073/pnas.89.12.5331. Proc Natl Acad Sci U S A. 1992. PMID: 1351680 Free PMC article.

• Structure and dynamics of zymogen human blood coagulation factor X.

  Venkateswarlu D, Perera L, Darden T, Pedersen LG. Venkateswarlu D, et al. Biophys J. 2002 Mar;82(3):1190-206. doi: 10.1016/S0006-3495(02)75476-3. Biophys J. 2002. PMID: 11867437 Free PMC article.

• Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion.

  Watzke HH, Wallmark A, Hamaguchi N, Giardina P, Stafford DW, High KA. Watzke HH, et al. J Clin Invest. 1991 Nov;88(5):1685-9. doi: 10.1172/JCI115484. J Clin Invest. 1991. PMID: 1939653 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • GlyGen glycoinformatics resource

• Miscellaneous

  • NCI CPTAC Assay Portal